Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4755,DB00065,Infliximab
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4756,DB00065,Infliximab
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4757,DB00065,Infliximab
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4758,DB00065,Infliximab
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4759,DB00065,Infliximab
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4760,DB00065,Infliximab
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4761,DB00065,Infliximab
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4762,DB00065,Infliximab
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4763,DB00065,Infliximab
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4764,DB00065,Infliximab
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4765,DB00065,Infliximab
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4766,DB00065,Infliximab
,31657711,total clearance (CL,"PPK estimates (estimated value, RSE%) were total clearance (CL: 0.018 L/h, 9.1) and volumes of distribution (Vd: 7.35 L, 12.0).",Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics . ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31657711/),[l] / [h],0.018,6280,DB00065,Infliximab
,31657711,volumes of distribution (Vd,"PPK estimates (estimated value, RSE%) were total clearance (CL: 0.018 L/h, 9.1) and volumes of distribution (Vd: 7.35 L, 12.0).",Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics . ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31657711/),l,7.35,6281,DB00065,Infliximab
,31657711,volumes of distribution (Vd,"PPK estimates (estimated value, RSE%) were total clearance (CL: 0.018 L/h, 9.1) and volumes of distribution (Vd: 7.35 L, 12.0).",Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics . ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31657711/),,12.0,6282,DB00065,Infliximab
,32905628,baseline clearance,Infliximab pharmacokinetics were well described by a 2-compartment model with linear mean estimated baseline clearance of 0.26 L/day.,Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905628/),[l] / [d],0.26,7264,DB00065,Infliximab
,33290108,TL,"The precision group (PG) received IFX dosing guided by a Bayesian pharmacokinetic model, aiming to achieve and maintain a TL of 3 µg/ml by treatment (de)escalation as indicated by the dashboard.",Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33290108/),[μg] / [ml],3,9203,DB00065,Infliximab
,32348905,clearance,"In 39 patients with ASUC, the median baseline calculated clearance was higher in patients requiring colectomy at 6 months than in patients without colectomy (0.733 vs 0.569 L/d; P = .005).",Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32348905/),[l] / [d],0.733,9236,DB00065,Infliximab
,32348905,clearance,"In 39 patients with ASUC, the median baseline calculated clearance was higher in patients requiring colectomy at 6 months than in patients without colectomy (0.733 vs 0.569 L/d; P = .005).",Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32348905/),[l] / [d],0.569,9237,DB00065,Infliximab
,32348905,clearance,"An infliximab clearance threshold of 0.627 L/d identified patients who required colectomy with 80.0% sensitivity and 82.8% specificity (area under the curve, 0.80).",Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32348905/),[l] / [d],0.627,9238,DB00065,Infliximab
,32348905,clearance,A higher proportion of patients with infliximab clearance of 0.627 L/d or more underwent colectomy within 6 months (61.5%) than patients with lower infliximab clearance values (7.7%) (P = .001).,Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32348905/),[l] / [d],0.627,9239,DB00065,Infliximab
,31284794,Clearance (CL),"Clearance (CL) estimates were 0.014 L/h and 0.015 L/h for PF-SZ-IFX and ref-IFX-EU, with inter-individual variability (IIV) on CL of 43.1% and 40.1%, respectively.",Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31284794/),[l] / [h],0.014,15297,DB00065,Infliximab
,31284794,Clearance (CL),"Clearance (CL) estimates were 0.014 L/h and 0.015 L/h for PF-SZ-IFX and ref-IFX-EU, with inter-individual variability (IIV) on CL of 43.1% and 40.1%, respectively.",Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31284794/),[l] / [h],0.015,15298,DB00065,Infliximab
,31284794,Volumes of distribution in the central compartment (V1),"Volumes of distribution in the central compartment (V1) were 3.38 L and 3.57 L, with IIV on V1 of 28.1% and 23.7%, respectively.",Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31284794/),l,3.38,15299,DB00065,Infliximab
,31284794,Volumes of distribution in the central compartment (V1),"Volumes of distribution in the central compartment (V1) were 3.38 L and 3.57 L, with IIV on V1 of 28.1% and 23.7%, respectively.",Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31284794/),l,3.57,15300,DB00065,Infliximab
,31316779,TLs,"At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.31), whereas median residual infliximab TLs were 0.5 µg/ml and 0 µg/ml (p = 0.034).",Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316779/),[μg] / [ml],21.9,20288,DB00065,Infliximab
,31316779,TLs,"At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.31), whereas median residual infliximab TLs were 0.5 µg/ml and 0 µg/ml (p = 0.034).",Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316779/),[μg] / [ml],24.9,20289,DB00065,Infliximab
,31316779,TLs,"At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.31), whereas median residual infliximab TLs were 0.5 µg/ml and 0 µg/ml (p = 0.034).",Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316779/),[μg] / [ml],0.5,20290,DB00065,Infliximab
,31316779,TLs,"At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.31), whereas median residual infliximab TLs were 0.5 µg/ml and 0 µg/ml (p = 0.034).",Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316779/),[μg] / [ml],0,20291,DB00065,Infliximab
,27589009,volume of distribution (V),"In AS patients, volume of distribution (V) and elimination clearance (CL) were 5.4 L and 0.24 L/day, respectively.",The underlying inflammatory chronic disease influences infliximab pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27589009/),l,5.4,29968,DB00065,Infliximab
,27589009,elimination clearance (CL),"In AS patients, volume of distribution (V) and elimination clearance (CL) were 5.4 L and 0.24 L/day, respectively.",The underlying inflammatory chronic disease influences infliximab pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27589009/),[l] / [d],0.24,29969,DB00065,Infliximab
,29659758,half-life [T1/2],The estimated effective IFX half-life [T1/2] (median [range]) and clearance (median [range]) were 8.42 [3.94-22.03] days and 0.50 [0.19-1.41] L/day respectively.,Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659758/),d,8.42,33648,DB00065,Infliximab
,29659758,clearance,The estimated effective IFX half-life [T1/2] (median [range]) and clearance (median [range]) were 8.42 [3.94-22.03] days and 0.50 [0.19-1.41] L/day respectively.,Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659758/),[l] / [d],0.50,33649,DB00065,Infliximab
,28195852,trough level,ATIs were detected in 75/332 (23%) patients; insufficient exposure below an IFX trough level of 3 μg/mL was the most predictive factor of developing ATI and resulted in a 4-fold increased risk of ATI development.,A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28195852/),[μg] / [ml],3,34547,DB00065,Infliximab
,30634202,CAUCendoscopy,"The model predicted that 70% of patients will attain mucosal healing with infliximab administered at days 0, 14 and 42 and a target CAUCendoscopy of 3752 mg/L*day at day 84.",Optimising infliximab induction dosing for patients with ulcerative colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30634202/),[mg] / [d·l],3752,37903,DB00065,Infliximab
,31489538,clearance,Typical clearance of infliximab was 0.404 L day-1 and increased with the presence of anti-drug antibodies and with lower albumin concentrations.,Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31489538/),[l] / [d],0.404,39044,DB00065,Infliximab
,31489538,Bmax,Estimate for TNF baseline (Bmax was 19.8 pg mL-1 and the dissociation constant (Kss) was 13.6 nM.,Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31489538/),[pg] / [ml],19.8,39045,DB00065,Infliximab
,31489538,dissociation constant (Kss),Estimate for TNF baseline (Bmax was 19.8 pg mL-1 and the dissociation constant (Kss) was 13.6 nM.,Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31489538/),nM,13.6,39046,DB00065,Infliximab
,17437161,distribution volume,"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),[l] / [kg],0.05,39821,DB00065,Infliximab
,17437161,elimination half-life (t (1/2)),"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),d,9.5,39822,DB00065,Infliximab
,27739008,trough concentrations,Bayesian algorithms were used to forecast individualized troughs and determine optimal dosing to maintain target trough concentrations (3 μg/mL).,Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27739008/),[μg] / [ml],3,41974,DB00065,Infliximab
,26952037,C(max),PK parameters (geometric mean) for BOW015 vs. rIFX were as follows; C(max) 142.47 vs.,"Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26952037/),,142.47,48557,DB00065,Infliximab
,26952037,AUC(0-t),"126.74 μg/mL, AUC(0-t) 36,211 vs. 34,304 h×μg/mL, and AUC(0-inf) 36,775 vs. 34,801 h×μg/mL.","Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26952037/),[h·μg] / [ml],"36,211",48558,DB00065,Infliximab
,26952037,AUC(0-t),"126.74 μg/mL, AUC(0-t) 36,211 vs. 34,304 h×μg/mL, and AUC(0-inf) 36,775 vs. 34,801 h×μg/mL.","Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26952037/),[h·μg] / [ml],"34,304",48559,DB00065,Infliximab
,26952037,AUC(0-inf),"126.74 μg/mL, AUC(0-t) 36,211 vs. 34,304 h×μg/mL, and AUC(0-inf) 36,775 vs. 34,801 h×μg/mL.","Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26952037/),[h·μg] / [ml],"36,775",48560,DB00065,Infliximab
,26952037,AUC(0-inf),"126.74 μg/mL, AUC(0-t) 36,211 vs. 34,304 h×μg/mL, and AUC(0-inf) 36,775 vs. 34,801 h×μg/mL.","Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26952037/),[h·μg] / [ml],"34,801",48561,DB00065,Infliximab
,21741088,clearance (CL),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],5.43,57365,DB00065,Infliximab
,21741088,V(d) in the central compartment (V(1)),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],54.2,57366,DB00065,Infliximab
,21741088,V(d) in the peripheral compartment (V(2)),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],29.2,57367,DB00065,Infliximab
,21741088,intercompartmental clearance (Q),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],3.52,57368,DB00065,Infliximab
,21741088,CL,"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],5.39,57369,DB00065,Infliximab
,21741088,V(1),"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],52.7,57370,DB00065,Infliximab
,21741088,V(2),"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],19.0,57371,DB00065,Infliximab
,21741088,Q,"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],2.15,57372,DB00065,Infliximab
,21741088,t(1/2),"In the pediatric and adult patients, observed trough serum infliximab concentrations, median infliximab t(1/2) (in children, 13.2 days; and in adults, 12.4 days), and exploratory PK simulations predicted infliximab PK properties to be comparable between children and adults.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),d,13.2,57373,DB00065,Infliximab
,21741088,t(1/2),"In the pediatric and adult patients, observed trough serum infliximab concentrations, median infliximab t(1/2) (in children, 13.2 days; and in adults, 12.4 days), and exploratory PK simulations predicted infliximab PK properties to be comparable between children and adults.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),d,12.4,57374,DB00065,Infliximab
<,23419382,trough level,An IFX trough level at week 14<2.2 μg/ml predicted IFX discontinuation due to persistent loss of response (LOR) or hypersensitivity reactions with 74% specificity and 82% sensitivity (likelihood ratio 3.1; P=0.0026).,Antibody response to infliximab and its impact on pharmacokinetics can be transient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23419382/),[μg] / [ml],2.2,65910,DB00065,Infliximab
,26545802,serum concentrations,"The median serum concentrations of infliximab at week 6 were 8.1 μg/mL in responders (interquartile range, 3.0-13.7 μg/mL) and 2.9 μg/mL in nonresponders (interquartile range, 0.01-5.8 μg/mL) (P = .03).",Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26545802/),[μg] / [ml],8.1,68832,DB00065,Infliximab
,26545802,serum concentrations,"The median serum concentrations of infliximab at week 6 were 8.1 μg/mL in responders (interquartile range, 3.0-13.7 μg/mL) and 2.9 μg/mL in nonresponders (interquartile range, 0.01-5.8 μg/mL) (P = .03).",Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26545802/),[μg] / [ml],2.9,68833,DB00065,Infliximab
,26545802,drug exposure,Patients with a baseline concentration of CRP greater than 50 mg/L had lower drug exposure from weeks 0 to 6 (587 mg/L/d in patients with high levels of CRP vs 1361 mg/L/day in patients with low CRP; P = .001).,Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26545802/),[mg] / [d·l],587,68834,DB00065,Infliximab
,26545802,drug exposure,Patients with a baseline concentration of CRP greater than 50 mg/L had lower drug exposure from weeks 0 to 6 (587 mg/L/d in patients with high levels of CRP vs 1361 mg/L/day in patients with low CRP; P = .001).,Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26545802/),[mg] / [d·l],1361,68835,DB00065,Infliximab
,26545802,area under the curve,The median area under the curve for serum concentration of infliximab during induction therapy was 1230 mg/L/d in nonresponders vs 1352 mg/L/d in responders (P = .65).,Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26545802/),[mg] / [d·l],1230,68836,DB00065,Infliximab
,26545802,area under the curve,The median area under the curve for serum concentration of infliximab during induction therapy was 1230 mg/L/d in nonresponders vs 1352 mg/L/d in responders (P = .65).,Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26545802/),[mg] / [d·l],1352,68837,DB00065,Infliximab
,24955449,lev l,"Patients receiving greater than 2.0 mg/kg of azathioprine had greater IFX lev l than those receiving less than 2.0 mg/kg (26.0 vs 10.6 mcg/mL, P = 0.03) and those receiving IFX monotherapy (26.0 vs 11.2 mcg/mL, P = 0.03).","Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24955449/),[mcg] / [ml],26.0,73572,DB00065,Infliximab
,24955449,lev l,"Patients receiving greater than 2.0 mg/kg of azathioprine had greater IFX lev l than those receiving less than 2.0 mg/kg (26.0 vs 10.6 mcg/mL, P = 0.03) and those receiving IFX monotherapy (26.0 vs 11.2 mcg/mL, P = 0.03).","Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24955449/),[mcg] / [ml],10.6,73573,DB00065,Infliximab
,24955449,lev l,"Patients receiving greater than 2.0 mg/kg of azathioprine had greater IFX lev l than those receiving less than 2.0 mg/kg (26.0 vs 10.6 mcg/mL, P = 0.03) and those receiving IFX monotherapy (26.0 vs 11.2 mcg/mL, P = 0.03).","Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24955449/),[mcg] / [ml],11.2,73574,DB00065,Infliximab
,17655372,clinical response rates,"In controlled trials, clinical response rates of 20-40% have been achieved with such regimens in Crohn's disease and rheumatoid arthritis.",Clinical pharmacokinetics and use of infliximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),%,20-40,73675,DB00065,Infliximab
,17655372,apparent volume of distribution,The apparent volume of distribution of the high-molecular-weight infliximab (149.1 kDa) is low (3-6L) and represents the intravascular space.,Clinical pharmacokinetics and use of infliximab. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),l,149.1,73676,DB00065,Infliximab
,17655372,apparent volume of distribution,The apparent volume of distribution of the high-molecular-weight infliximab (149.1 kDa) is low (3-6L) and represents the intravascular space.,Clinical pharmacokinetics and use of infliximab. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),l,3-6,73677,DB00065,Infliximab
,17655372,elimination half-life,"The long persistence in this compartment (elimination half-life 7-12 days, mean residence time 12-17 days) is due to the very low systemic clearance of about 11-15 mL/hour (0.18-0.25 mL/minute).",Clinical pharmacokinetics and use of infliximab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),d,7-12,73678,DB00065,Infliximab
,17655372,mean residence time,"The long persistence in this compartment (elimination half-life 7-12 days, mean residence time 12-17 days) is due to the very low systemic clearance of about 11-15 mL/hour (0.18-0.25 mL/minute).",Clinical pharmacokinetics and use of infliximab. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),d,12-17,73679,DB00065,Infliximab
,17655372,systemic clearance,"The long persistence in this compartment (elimination half-life 7-12 days, mean residence time 12-17 days) is due to the very low systemic clearance of about 11-15 mL/hour (0.18-0.25 mL/minute).",Clinical pharmacokinetics and use of infliximab. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),[ml] / [h],11-15,73680,DB00065,Infliximab
above,17655372,trough concentrations,"When relating serum concentrations to the clinical response in patients with rheumatoid arthritis and patients with Crohn's disease, it can be assumed that trough concentrations above 1 microg/mL could be used as a kind of therapeutic target.",Clinical pharmacokinetics and use of infliximab. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),[μg] / [ml],1,73681,DB00065,Infliximab
,32200087,trough level,"The mean infliximab trough level was 5.46 mg/L, and the mean ΣAUC was 3938 ± 1427 mg.d/L.","Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200087/),[mg] / [l],5.46,74765,DB00065,Infliximab
,32200087,ΣAUC,"The mean infliximab trough level was 5.46 mg/L, and the mean ΣAUC was 3938 ± 1427 mg.d/L.","Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200087/),[d·mg] / [l],3938,74766,DB00065,Infliximab
above,32200087,ΣAUC,"Factors independently associated with infection after multivariate analysis were smoking (odds ratio [OR], 2.05; P = .046), IBD flare (OR, 2.71; P = .006), and a high ΣAUC of infliximab (above 3234 mg x d/L) (OR, 2.02; P = .02).","Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200087/),[d·mg] / [l],3234,74767,DB00065,Infliximab
,23687259,AUC,Geometric mean AUC was 32 765.8 μgh/ml for CT-P13 and 31 359.3 μgh/ml for INX.,"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),[μgh] / [ml],32 765.8,76222,DB00065,Infliximab
,23687259,AUC,Geometric mean AUC was 32 765.8 μgh/ml for CT-P13 and 31 359.3 μgh/ml for INX.,"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),[μgh] / [ml],31 359.3,76223,DB00065,Infliximab
,23687259,"Cmax,ss","Geometric mean Cmax,ss was 147.0 μg/ml for CT-P13 and 144.8 μg/ml for INX.","A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),[μg] / [ml],147.0,76224,DB00065,Infliximab
,23687259,"Cmax,ss","Geometric mean Cmax,ss was 147.0 μg/ml for CT-P13 and 144.8 μg/ml for INX.","A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),[μg] / [ml],144.8,76225,DB00065,Infliximab
,23687259,responses,"ASAS20 and ASAS40 responses at week 30 were 70.5% and 51.8% for CT-P13 and 72.4% and 47.4% for INX, respectively.","A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),%,70.5,76226,DB00065,Infliximab
,23687259,responses,"ASAS20 and ASAS40 responses at week 30 were 70.5% and 51.8% for CT-P13 and 72.4% and 47.4% for INX, respectively.","A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),%,51.8,76227,DB00065,Infliximab
,23687259,responses,"ASAS20 and ASAS40 responses at week 30 were 70.5% and 51.8% for CT-P13 and 72.4% and 47.4% for INX, respectively.","A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),%,72.4,76228,DB00065,Infliximab
,23687259,responses,"ASAS20 and ASAS40 responses at week 30 were 70.5% and 51.8% for CT-P13 and 72.4% and 47.4% for INX, respectively.","A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687259/),%,47.4,76229,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],35,76820,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],21,76821,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],20.1,76822,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],11,76823,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],6.6,76824,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],2.9,76825,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],4.3,76826,DB00065,Infliximab
,33051546,trough levels,"Originator trough levels were higher than the biosimilar trough levels (35 vs. 21, 20.1 vs. 11, 6.6 vs. 2.9 and 4.3 vs. 1.7 μg/mL at weeks 2, 6, 14 and 22, respectively).",Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051546/),[μg] / [ml],1.7,76827,DB00065,Infliximab
,17618323,overall response rate,The overall response rate in 22 evaluable children was 82% (12 CR+6 PR).,Infliximab for GVHD therapy in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17618323/),%,82,77902,DB00065,Infliximab
<,32813123,trough levels,"At the start of maintenance treatment, 72% of YP had trough levels below therapeutic range (< 5.4 μg/mL).",Infliximab in young paediatric IBD patients: it is all about the dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32813123/),[μg] / [ml],5.4,80905,DB00065,Infliximab
,33354765,AUC,"The optimal infliximab AUC target during induction for week 14 biochemical remission was 79,348 µg*h/mL (area under the receiver operating characteristic curve (AUROC) 0.77, [0.63-0.90], 85.7% sensitive, and 64.3% specific) with those exceeding the AUC target more likely to achieve a surgery-free week 52 biochemical remission (OR 4.3, [1.2-14.6]).",Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354765/),[h·μg] / [ml],"79,348",82957,DB00065,Infliximab
,33115797,clearance,"The median (IQR) clearance estimated for the infliximab originator before the change was 0.364 (0.321-0.415) L/day, and for the CT-P13 biosimilar it was 0.361 (0.323-0.415) L/day 4-8 weeks after the change, and 0.370 (0.334-0.419) L/day 2 years after (p=0.395).",Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115797/),[l] / [d],0.364,87891,DB00065,Infliximab
,33115797,clearance,"The median (IQR) clearance estimated for the infliximab originator before the change was 0.364 (0.321-0.415) L/day, and for the CT-P13 biosimilar it was 0.361 (0.323-0.415) L/day 4-8 weeks after the change, and 0.370 (0.334-0.419) L/day 2 years after (p=0.395).",Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115797/),[l] / [d],0.361,87892,DB00065,Infliximab
,33115797,clearance,"The median (IQR) clearance estimated for the infliximab originator before the change was 0.364 (0.321-0.415) L/day, and for the CT-P13 biosimilar it was 0.361 (0.323-0.415) L/day 4-8 weeks after the change, and 0.370 (0.334-0.419) L/day 2 years after (p=0.395).",Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115797/),[l] / [d],0.370,87893,DB00065,Infliximab
,30997153,response rates,"At week 54, the American College of Rheumatology (ACR20) response rates were 71.1% (PF-SZ-IFX/PF-SZ-IFX), 64.3% (ref-IFX/ref-IFX) and 70.6% (ref-IFX/PF-SZ-IFX).","Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30997153/),%,71.1,90980,DB00065,Infliximab
,30997153,response rates,"At week 54, the American College of Rheumatology (ACR20) response rates were 71.1% (PF-SZ-IFX/PF-SZ-IFX), 64.3% (ref-IFX/ref-IFX) and 70.6% (ref-IFX/PF-SZ-IFX).","Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30997153/),%,64.3,90981,DB00065,Infliximab
,30997153,response rates,"At week 54, the American College of Rheumatology (ACR20) response rates were 71.1% (PF-SZ-IFX/PF-SZ-IFX), 64.3% (ref-IFX/ref-IFX) and 70.6% (ref-IFX/PF-SZ-IFX).","Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30997153/),%,70.6,90982,DB00065,Infliximab
,15647331,terminal half-life,The terminal half-life of the anti-IFX IgG antibody immune complex was approximately 38 h compared with 86 h for the nonimmune antibody.,"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647331/),h,38,94275,DB00065,Infliximab
,15647331,terminal half-life,The terminal half-life of the anti-IFX IgG antibody immune complex was approximately 38 h compared with 86 h for the nonimmune antibody.,"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647331/),h,86,94276,DB00065,Infliximab
,34351609,R,"Estimated baseline TNF-α amounts were similar in Crohn's disease and rheumatoid arthritis (R0 = 0.39 vs 0.46 nM, respectively), but infliximab-TNF complex elimination was slower in Crohn's disease than in rheumatoid arthritis (kint = 0.024 vs 0.061 day-1, respectively).",Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34351609/),,0,99205,DB00065,Infliximab
,34351609,kint,"Estimated baseline TNF-α amounts were similar in Crohn's disease and rheumatoid arthritis (R0 = 0.39 vs 0.46 nM, respectively), but infliximab-TNF complex elimination was slower in Crohn's disease than in rheumatoid arthritis (kint = 0.024 vs 0.061 day-1, respectively).",Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34351609/),1/[d],0.024,99206,DB00065,Infliximab
,34351609,kint,"Estimated baseline TNF-α amounts were similar in Crohn's disease and rheumatoid arthritis (R0 = 0.39 vs 0.46 nM, respectively), but infliximab-TNF complex elimination was slower in Crohn's disease than in rheumatoid arthritis (kint = 0.024 vs 0.061 day-1, respectively).",Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34351609/),1/[d],0.061,99207,DB00065,Infliximab
,34351609,Terminal elimination half-lives,"Terminal elimination half-lives were 13.5, 21.5 and 16.5 days for rheumatoid arthritis, Crohn's disease and ankylosing spondylitis, respectively.",Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34351609/),d,13.5,99208,DB00065,Infliximab
,34351609,Terminal elimination half-lives,"Terminal elimination half-lives were 13.5, 21.5 and 16.5 days for rheumatoid arthritis, Crohn's disease and ankylosing spondylitis, respectively.",Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34351609/),d,21.5,99209,DB00065,Infliximab
,34351609,Terminal elimination half-lives,"Terminal elimination half-lives were 13.5, 21.5 and 16.5 days for rheumatoid arthritis, Crohn's disease and ankylosing spondylitis, respectively.",Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34351609/),d,16.5,99210,DB00065,Infliximab
,22792380,IC(50),"In vitro, 200 nM D1(A12) inhibited shedding of ADAM17 substrates TNF-α, TNFR1-α, TGF-α, amphiregulin (AREG), HB-EGF and IL-6Rα, from IGROV1-Luc cells, (4.7 nM IC(50) for TNF-α shedding).",Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22792380/),nM,4.7,113675,DB00065,Infliximab
,22792380,plasma half life,The plasma half life was 8.6 days.,Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22792380/),d,8.6,113676,DB00065,Infliximab
>,28471911,trough,"At standard maintenance dosing of 5 mg/kg every 8 weeks, a trough >3 μg/mL was predicted to be achieved in 32% of patients.",Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28471911/),[μg] / [ml],3,116124,DB00065,Infliximab
>,28471911,trough,"To achieve a trough >3 μg/mL, a dosing interval ≤every 6 weeks was predicted to be required in 29% of patients.",Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28471911/),[μg] / [ml],3,116125,DB00065,Infliximab
,28318043,trough infliximab concentrations,"Median trough infliximab concentrations were 8.50 μg/mL (IQR: 7.23-10.07 μg/mL), 10.31 μg/mL (IQR: 7.66-15.63 μg/mL) and 21.02 μg/mL (IQR: 16.01-26.70 μg/mL) at trimesters 1, 2 and 3 respectively.",The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28318043/),[μg] / [ml],8.50,124393,DB00065,Infliximab
,28318043,trough infliximab concentrations,"Median trough infliximab concentrations were 8.50 μg/mL (IQR: 7.23-10.07 μg/mL), 10.31 μg/mL (IQR: 7.66-15.63 μg/mL) and 21.02 μg/mL (IQR: 16.01-26.70 μg/mL) at trimesters 1, 2 and 3 respectively.",The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28318043/),[μg] / [ml],10.31,124394,DB00065,Infliximab
,28318043,trough infliximab concentrations,"Median trough infliximab concentrations were 8.50 μg/mL (IQR: 7.23-10.07 μg/mL), 10.31 μg/mL (IQR: 7.66-15.63 μg/mL) and 21.02 μg/mL (IQR: 16.01-26.70 μg/mL) at trimesters 1, 2 and 3 respectively.",The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28318043/),[μg] / [ml],21.02,124395,DB00065,Infliximab
<,30860594,trough,"Independent predictors of relapse were tobacco use and/or ulcerative colitis (P = 0.0093), a higher C-reactive protein (CRP; P = 0.00064), and an infliximab trough < 2.4 μg/mL after de-escalation (P = 0.0001).",Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30860594/),[μg] / [ml],2.4,126888,DB00065,Infliximab
>,30860594,trough,"Patients with trough > 5.7 μg/mL are eligible to de-escalation, but infliximab pharmacokinetics is highly variable in time.",Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30860594/),[μg] / [ml],5.7,126889,DB00065,Infliximab
>,30860594,trough,"Therefore, drug monitoring is mandatory after de-escalation to maintain trough > 2.4 μg/mL.",Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30860594/),[μg] / [ml],2.4,126890,DB00065,Infliximab
,29623653,clearance,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),[l] / [d],0.117,130079,DB00065,Infliximab
,29623653,volume of distribution of the central (V1),"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),l,0.801,130080,DB00065,Infliximab
,29623653,peripheral (V2) compartment,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),l,0.801,130081,DB00065,Infliximab
,29623653,intercompartmental clearance,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),l,0.962,130082,DB00065,Infliximab
,29623653,intercompartmental clearance,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),[l] / [d],0.692,130083,DB00065,Infliximab
,33604964,trough concentration,"Regardless of age, an infliximab trough concentration at week (w)14 of 15.6 mg/L was associated with a 50% probability of attaining endoscopic remission between w6 and w22.",The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33604964/),[mg] / [l],15.6,131446,DB00065,Infliximab
,18326743,half-life,The half-life of the drug was estimated to be 8.5 days.,A pilot study on ocular safety of intravitreal infliximab in a rabbit model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18326743/),d,8.5,133277,DB00065,Infliximab
under,21533855,trough concentrations,Six of the 9 primary nonresponders showed rapid clearance of infliximab: their trough concentrations of infliximab were under 1 μg/ml.,Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21533855/),[μg] / [ml],1,139355,DB00065,Infliximab
,16628126,Terminal elimination half-life,Terminal elimination half-life was 10.9 days.,An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628126/),d,10.9,151759,DB00065,Infliximab
,31073411,Trough IFX levels,Trough IFX levels decreased from 23.6 (day 10) to 2.5 μg/mL (day 23).,Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31073411/),[μg] / [ml],23.6,161247,DB00065,Infliximab
,31073411,Trough IFX levels,Trough IFX levels decreased from 23.6 (day 10) to 2.5 μg/mL (day 23).,Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31073411/),[μg] / [ml],2.5,161248,DB00065,Infliximab
,25733037,trough concentration,"Strategies 3 and 4 used Individualized doses, adjusted to albumin level, sex and body weight, and a fix interdose interval of 8 weeks to achieve a target trough concentration of 5 mg/L or 6 mg/L, respectively.",A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733037/),[mg] / [l],5,164122,DB00065,Infliximab
,25733037,trough concentration,"Strategies 3 and 4 used Individualized doses, adjusted to albumin level, sex and body weight, and a fix interdose interval of 8 weeks to achieve a target trough concentration of 5 mg/L or 6 mg/L, respectively.",A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733037/),[mg] / [l],6,164123,DB00065,Infliximab
,19756557,clearance (CL,"Population pharmacokinetic estimates (typical value +/- standard error), based on the final covariate model, were clearance (CL: 0.407 +/- 0.0103 L/day), apparent volumes of distribution in the central (V(1): 3.29 +/- 0.0679 L) and peripheral (V(2): 4.13 +/- 0.16 L) compartments, and intercompartment clearance (Q: 7.14 +/- 0.489 L/day).",Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19756557/),[l] / [d],0.407,166042,DB00065,Infliximab
,19756557,apparent volumes of distribution in the central (V(1),"Population pharmacokinetic estimates (typical value +/- standard error), based on the final covariate model, were clearance (CL: 0.407 +/- 0.0103 L/day), apparent volumes of distribution in the central (V(1): 3.29 +/- 0.0679 L) and peripheral (V(2): 4.13 +/- 0.16 L) compartments, and intercompartment clearance (Q: 7.14 +/- 0.489 L/day).",Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19756557/),l,3.29,166043,DB00065,Infliximab
,19756557,intercompartment clearance (Q,"Population pharmacokinetic estimates (typical value +/- standard error), based on the final covariate model, were clearance (CL: 0.407 +/- 0.0103 L/day), apparent volumes of distribution in the central (V(1): 3.29 +/- 0.0679 L) and peripheral (V(2): 4.13 +/- 0.16 L) compartments, and intercompartment clearance (Q: 7.14 +/- 0.489 L/day).",Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19756557/),[l] / [d],7.14,166044,DB00065,Infliximab
,19756557,t(1/2),Infliximab t(1/2) is approximately 14 days.,Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19756557/),d,14,166045,DB00065,Infliximab
,27091119,trough levels,"Mean infliximab trough levels at day 14 were significantly lower in patients with acute severe UC compared to moderately severe UC (7.15 ± 5.3 vs. 14.4 ± 11.2 μg/mL, P = 0.007).",Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27091119/),[μg] / [ml],7.15,169455,DB00065,Infliximab
,27091119,trough levels,"Mean infliximab trough levels at day 14 were significantly lower in patients with acute severe UC compared to moderately severe UC (7.15 ± 5.3 vs. 14.4 ± 11.2 μg/mL, P = 0.007).",Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27091119/),[μg] / [ml],14.4,169456,DB00065,Infliximab
,27091119,levels,"However, week 2 median antibody-to-infliximab levels were numerically higher among primary nonresponders (3.4 ± 5.7 vs. 1.2 ± 4 μg/mL-eq, respectively, P = 0.06).",Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27091119/),,3,169457,DB00065,Infliximab
,27091119,levels,"However, week 2 median antibody-to-infliximab levels were numerically higher among primary nonresponders (3.4 ± 5.7 vs. 1.2 ± 4 μg/mL-eq, respectively, P = 0.06).",Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27091119/),,1.2,169458,DB00065,Infliximab
,24913041,CR rates,"CR rates following IFX initiation were 6.9%, 25%, and 80% in groups A, B, and C, respectively (P<0.01 between groups C/A and between groups C/B).",Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24913041/),%,6.9,174380,DB00065,Infliximab
,24913041,CR rates,"CR rates following IFX initiation were 6.9%, 25%, and 80% in groups A, B, and C, respectively (P<0.01 between groups C/A and between groups C/B).",Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24913041/),%,25,174381,DB00065,Infliximab
,24913041,CR rates,"CR rates following IFX initiation were 6.9%, 25%, and 80% in groups A, B, and C, respectively (P<0.01 between groups C/A and between groups C/B).",Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24913041/),%,80,174382,DB00065,Infliximab
,24913041,Duration of response,"Duration of response to IFX was significantly higher in group C than in groups A and B (14 vs. 3 and 5 months, respectively, P<0.01).",Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24913041/),month,14,174383,DB00065,Infliximab
,24913041,Duration of response,"Duration of response to IFX was significantly higher in group C than in groups A and B (14 vs. 3 and 5 months, respectively, P<0.01).",Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24913041/),month,3,174384,DB00065,Infliximab
,24913041,Duration of response,"Duration of response to IFX was significantly higher in group C than in groups A and B (14 vs. 3 and 5 months, respectively, P<0.01).",Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24913041/),month,5,174385,DB00065,Infliximab
>,24913041,trough levels,"ADA trough levels >4.9 μg/ml are associated with failure of two anti-TNF agents (ADA and IFX) in 90% of cases, and switching to another drug class should be considered.",Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24913041/),[μg] / [ml],4.9,174386,DB00065,Infliximab
,24193155,trough serum infliximab concentrations,"At week 30, higher median trough serum infliximab concentrations were observed with infliximab 5 mg/kg q8w (1.9 μg/mL) versus q12w (0.8 μg/mL) and with infliximab 10 mg/kg (2.9 μg/mL) versus 5 mg/kg (1.1 μg/mL) among patients who are regimen adjusted.","Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24193155/),[μg] / [ml],1.9,175456,DB00065,Infliximab
,24193155,trough serum infliximab concentrations,"At week 30, higher median trough serum infliximab concentrations were observed with infliximab 5 mg/kg q8w (1.9 μg/mL) versus q12w (0.8 μg/mL) and with infliximab 10 mg/kg (2.9 μg/mL) versus 5 mg/kg (1.1 μg/mL) among patients who are regimen adjusted.","Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24193155/),[μg] / [ml],0.8,175457,DB00065,Infliximab
,24193155,trough serum infliximab concentrations,"At week 30, higher median trough serum infliximab concentrations were observed with infliximab 5 mg/kg q8w (1.9 μg/mL) versus q12w (0.8 μg/mL) and with infliximab 10 mg/kg (2.9 μg/mL) versus 5 mg/kg (1.1 μg/mL) among patients who are regimen adjusted.","Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24193155/),[μg] / [ml],2.9,175458,DB00065,Infliximab
,24193155,trough serum infliximab concentrations,"At week 30, higher median trough serum infliximab concentrations were observed with infliximab 5 mg/kg q8w (1.9 μg/mL) versus q12w (0.8 μg/mL) and with infliximab 10 mg/kg (2.9 μg/mL) versus 5 mg/kg (1.1 μg/mL) among patients who are regimen adjusted.","Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24193155/),[μg] / [ml],1.1,175459,DB00065,Infliximab
,10782805,terminal half-life,Infliximab in doses of 5 to 20 mg/kg had a mean terminal half-life ranging from 9 to 12 days and was detectable in sera from most patients 8 to 12 weeks after dosing.,Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10782805/),d,9 to 12,175874,DB00065,Infliximab
,31283556,Cmin,The median of the Cmin values was 3.62 mg/L (1.47-6.02).,Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31283556/),[mg] / [l],3.62,179239,DB00065,Infliximab
,31283556,AUC,"The predicted median AUC was 28,421 mg/h/L (22,336-36,903).",Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31283556/),[mg] / [h·l],"28,421",179240,DB00065,Infliximab
,31283556,CL,"The median individual predicted CL, K10, and t1/2 values were 4.77 mL/kg/day (3.88-5.90), 0.09 days (0.08-0.12), and 12.22 days (9.49-14.87), respectively.",Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31283556/),[ml] / [d·kg],4.77,179241,DB00065,Infliximab
,31283556,K10,"The median individual predicted CL, K10, and t1/2 values were 4.77 mL/kg/day (3.88-5.90), 0.09 days (0.08-0.12), and 12.22 days (9.49-14.87), respectively.",Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31283556/),d,0.09,179242,DB00065,Infliximab
,31283556,t1/2,"The median individual predicted CL, K10, and t1/2 values were 4.77 mL/kg/day (3.88-5.90), 0.09 days (0.08-0.12), and 12.22 days (9.49-14.87), respectively.",Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31283556/),d,12.22,179243,DB00065,Infliximab
,12269969,overall response,"The overall response, using a minimum decrease of 70 in the Crohn's disease activity index, was 41-47% for the evaluable group, at weeks 8 and 12.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),%,41-47,179281,DB00065,Infliximab
,12269969,partial thromboplastin time prolongation,"The 2-4-h transient post-infusion partial thromboplastin time prolongation values, a class effect of phosphorothioate oligonucleotides, were 18, 21 and 23 s for 250, 300 and 350 mg, respectively.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),s,18,179282,DB00065,Infliximab
,12269969,partial thromboplastin time prolongation,"The 2-4-h transient post-infusion partial thromboplastin time prolongation values, a class effect of phosphorothioate oligonucleotides, were 18, 21 and 23 s for 250, 300 and 350 mg, respectively.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),s,21,179283,DB00065,Infliximab
,12269969,partial thromboplastin time prolongation,"The 2-4-h transient post-infusion partial thromboplastin time prolongation values, a class effect of phosphorothioate oligonucleotides, were 18, 21 and 23 s for 250, 300 and 350 mg, respectively.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),s,23,179284,DB00065,Infliximab
,15372221,Maximal serum concentrations,"Maximal serum concentrations of infliximab at 1, 3 and 5 weeks were (mean+/-SD) 108+/-11, 135+/-19, and 139+/-6 microg/ml, respectively, and appeared similar to historical concentrations from non-cancer patients not receiving concomitant chemotherapy (144+/-68 microg/ml).",A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372221/),[μg] / [ml],108,187903,DB00065,Infliximab
,15372221,Maximal serum concentrations,"Maximal serum concentrations of infliximab at 1, 3 and 5 weeks were (mean+/-SD) 108+/-11, 135+/-19, and 139+/-6 microg/ml, respectively, and appeared similar to historical concentrations from non-cancer patients not receiving concomitant chemotherapy (144+/-68 microg/ml).",A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372221/),[μg] / [ml],135,187904,DB00065,Infliximab
,15372221,Maximal serum concentrations,"Maximal serum concentrations of infliximab at 1, 3 and 5 weeks were (mean+/-SD) 108+/-11, 135+/-19, and 139+/-6 microg/ml, respectively, and appeared similar to historical concentrations from non-cancer patients not receiving concomitant chemotherapy (144+/-68 microg/ml).",A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372221/),[μg] / [ml],139,187905,DB00065,Infliximab
,15372221,Maximal serum concentrations,"Maximal serum concentrations of infliximab at 1, 3 and 5 weeks were (mean+/-SD) 108+/-11, 135+/-19, and 139+/-6 microg/ml, respectively, and appeared similar to historical concentrations from non-cancer patients not receiving concomitant chemotherapy (144+/-68 microg/ml).",A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372221/),[μg] / [ml],144,187906,DB00065,Infliximab
,15372221,survival,Median survival within the cohort was 203 days (range 111 to 324 days).,A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372221/),d,203,187907,DB00065,Infliximab
,33486961,withdrawal,"At week 54, the withdrawal rates for the reference IFX and CPT-13 were 11.5% and 20.0%, respectively (p=0.226), while at week 104 they were 26.2% and 28.9% (p=0.761).","Biosimilar infliximab CPT-13 in inflammatory bowel disease in real clinical setting: pharmacokinetics outcomes, immunogenicity and drug survival. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486961/),,11,190915,DB00065,Infliximab
,33486961,withdrawal,"At week 54, the withdrawal rates for the reference IFX and CPT-13 were 11.5% and 20.0%, respectively (p=0.226), while at week 104 they were 26.2% and 28.9% (p=0.761).","Biosimilar infliximab CPT-13 in inflammatory bowel disease in real clinical setting: pharmacokinetics outcomes, immunogenicity and drug survival. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486961/),,26,190916,DB00065,Infliximab
,18401017,clearance (CL,"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),[l] / [d],0.273,196260,DB00065,Infliximab
,18401017,volume of distribution in the central compartment (V(1),"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),l,3.06,196261,DB00065,Infliximab
,18401017,intercompartment clearance (Q,"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),[l] / [d],1.72,196262,DB00065,Infliximab
,18401017,volume of distribution in the peripheral compartment (V(2),"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),l,2.94,196263,DB00065,Infliximab
,28879645,clearance,Infliximab clearance was increased in subjects with ADAs vs. those without ADAs (12.89 ± 2.69 vs. 9.90 ± 1.74 ml/h; p < 0.0005).,Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28879645/),[ml] / [h],12.89,198262,DB00065,Infliximab
,28879645,clearance,Infliximab clearance was increased in subjects with ADAs vs. those without ADAs (12.89 ± 2.69 vs. 9.90 ± 1.74 ml/h; p < 0.0005).,Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28879645/),[ml] / [h],9.90,198263,DB00065,Infliximab
,28879645,elimination half-time,The elimination half-time was shorter in subjects with ADAs (282.4 ± 56.4 vs. 343.3 ± 61.9 h; p < 0.01).,Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28879645/),h,282.4,198264,DB00065,Infliximab
,28879645,elimination half-time,The elimination half-time was shorter in subjects with ADAs (282.4 ± 56.4 vs. 343.3 ± 61.9 h; p < 0.01).,Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28879645/),h,343.3,198265,DB00065,Infliximab
,33079627,volume of distribution n,A one-compartment model with linear elimination described the pharmacokinetics of infliximab (volume of distribution n = 18.2 L; clearance 0.61 L/day).,Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33079627/),l,18.2,203889,DB00065,Infliximab
,33079627,clearance,A one-compartment model with linear elimination described the pharmacokinetics of infliximab (volume of distribution n = 18.2 L; clearance 0.61 L/day).,Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33079627/),[l] / [d],0.61,203890,DB00065,Infliximab
,27585978,C max,"At this dose, C max was 1360 µg/mL and AUC at 168 h was 115,000 µg h/mL on day 8.",Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27585978/),[μg] / [ml],1360,210135,DB00065,Infliximab
,27585978,AUC at 168 h,"At this dose, C max was 1360 µg/mL and AUC at 168 h was 115,000 µg h/mL on day 8.",Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27585978/),[h·μg] / [ml],"115,000",210136,DB00065,Infliximab
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB00065,Infliximab
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB00065,Infliximab
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB00065,Infliximab
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB00065,Infliximab
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB00065,Infliximab
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB00065,Infliximab
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB00065,Infliximab
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB00065,Infliximab
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB00065,Infliximab
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB00065,Infliximab
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB00065,Infliximab
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB00065,Infliximab
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB00065,Infliximab
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB00065,Infliximab
,18641542,population distribution,"Mean population distribution and elimination half-lives were 4.3 and 18.5 days, respectively.",Infliximab pharmacokinetics in inflammatory bowel disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641542/),d,4.3,218646,DB00065,Infliximab
,18641542,elimination half-lives,"Mean population distribution and elimination half-lives were 4.3 and 18.5 days, respectively.",Infliximab pharmacokinetics in inflammatory bowel disease patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641542/),d,18.5,218647,DB00065,Infliximab
,18641542,elimination half-life,"Infliximab pharmacokinetics are similar to those of other monoclonal antibodies, notably with an elimination half-life of approximately 3 weeks.",Infliximab pharmacokinetics in inflammatory bowel disease patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641542/),weeks,3,218648,DB00065,Infliximab
,25358062,CL,The typical IFX-CL was 0.381 L/d.,Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358062/),[l] / [d],0.381,224355,DB00065,Infliximab
,25358062,effective half-life,The estimated median IFX effective half-life was 5.6 ± 2.4 days.,Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358062/),d,5.6,224356,DB00065,Infliximab
≥,26113313,trough levels,Several publications indicate that IFX should be dosed on trough levels ≥3.0 mg/L.,Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26113313/),[mg] / [l],3.0,225824,DB00065,Infliximab
≥,26113313,trough levels,Our results show that in patients without ATI target trough levels ≥3.0 mg/L can be achieved by increasing dosing intervals from 8 to 12 weeks combined with a dose increase.,Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26113313/),[mg] / [l],3.0,225825,DB00065,Infliximab
,30633088,trough level,The median baseline IFX trough level was 5.7 mcg/mL (3.8-9.3) versus 6.5 mcg/mL (3.9-8.6) at month 6 after switching (P = 0.900).,"Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633088/),[mcg] / [ml],5.7,245084,DB00065,Infliximab
,30633088,trough level,The median baseline IFX trough level was 5.7 mcg/mL (3.8-9.3) versus 6.5 mcg/mL (3.9-8.6) at month 6 after switching (P = 0.900).,"Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633088/),[mcg] / [ml],6.5,245085,DB00065,Infliximab
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,96,248802,DB00065,Infliximab
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,97,248803,DB00065,Infliximab
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,90,248804,DB00065,Infliximab
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,83,248805,DB00065,Infliximab
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,74,248806,DB00065,Infliximab
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,75,248807,DB00065,Infliximab
,30784100,trough levels,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),[μg] / [ml],1.7,248808,DB00065,Infliximab
,30784100,trough levels,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),[μg] / [ml],5.0,248809,DB00065,Infliximab
,30784100,drug-to-trough ratio,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),,3.9,248810,DB00065,Infliximab
,30784100,drug-to-trough ratio,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),,1.5,248811,DB00065,Infliximab
,29226370,trough concentrations,Treatment intensification increased IFX trough concentrations from 1.2 μg/mL [0.3-3.6] at T0 to 3.6 μg/mL [0.5-10.2] at T+1 (P < .0001).,Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29226370/),[μg] / [ml],1.2,262661,DB00065,Infliximab
,29226370,trough concentrations,Treatment intensification increased IFX trough concentrations from 1.2 μg/mL [0.3-3.6] at T0 to 3.6 μg/mL [0.5-10.2] at T+1 (P < .0001).,Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29226370/),[μg] / [ml],3.6,262662,DB00065,Infliximab
≥,29226370,trough concentrations,"When ATI were quantifiable but <282 ng/mL eq. at T0, combined interval shortening and dose doubling was more effective for restoring therapeutic IFX trough concentrations (≥3 μg/mL at T+1) than dose doubling alone, which in turn was more effective than interval shortening alone (P < .001).",Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29226370/),[μg] / [ml],3,262663,DB00065,Infliximab
,21692827,volumes of distribution for the central compartment,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),l,2.4,263196,DB00065,Infliximab
,21692827,peripheral compartment,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),l,1.8,263197,DB00065,Infliximab
,21692827,systemic clearance,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),day⁻¹·l,0.23,263198,DB00065,Infliximab
,21692827,intercompartment clearance,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),day⁻¹·l,2.3,263199,DB00065,Infliximab
,24354889,central volume of distribution,The mean (interindividual standard deviation) estimated central volume of distribution was 2.3 l (36%) and systemic clearance was 0.019 l h(-1) (37%).,Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24354889/),l,2.3,265445,DB00065,Infliximab
,24354889,systemic clearance,The mean (interindividual standard deviation) estimated central volume of distribution was 2.3 l (36%) and systemic clearance was 0.019 l h(-1) (37%).,Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24354889/),[l] / [h],0.019,265446,DB00065,Infliximab
,34205175,half-life,"The infliximab half-life increased with R allele number (13.2, 14.4 and 15.6 days for HH, HR and RR patients, respectively).",Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34205175/),d,13.2,266819,DB00065,Infliximab
,34205175,half-life,"The infliximab half-life increased with R allele number (13.2, 14.4 and 15.6 days for HH, HR and RR patients, respectively).",Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34205175/),d,14.4,266820,DB00065,Infliximab
,34205175,half-life,"The infliximab half-life increased with R allele number (13.2, 14.4 and 15.6 days for HH, HR and RR patients, respectively).",Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34205175/),d,15.6,266821,DB00065,Infliximab
,31607268,partial,Median partial Mayo score was 6.0 at baseline and 4.0 at Week 30 (overall).,"Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31607268/),,6.0,267836,DB00065,Infliximab
,19474407,half-life,The vitreous half-life of infliximab was estimated to be 6.5 +/- 0.6 days.,Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19474407/),d,6.5,270356,DB00065,Infliximab
